In the last few years, Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry. With multiple programs now nearing proof-of-concept readouts, yet still “not happy about the pace” of development, Astellas is shifting its focus more to later-stage opportunities, chief strategy officer Adam Pearson said.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,